Scientific impact: Among the examples of the short-term impacts of the Action is the development of a multi-level CNP registry based on the availability of big data from different groups of CNP patients. A central repository can aggregate clinical, genetic, and treatment data, enabling a comprehensive view of the disease and its progression. Centralized data will ensure the efficient application of ML in the disclosure of biomarkers important for targeted therapies and custom-tailored interventions. Such a ML- driven support will have a long-term impact on decision making and treatment policies of CNP patients. The integration of nutritional factors with genomic and clinical data is expected to uncover new molecular mechanisms influencing neutrophil development. This research will provide insights into the genetic and metabolic regulation of neutrophil production, which can inform future diagnostic and therapeutic approaches.

Technological impact: Among the examples of the short-term technological impact of the Action are the standardized protocols adopted for CNP data sharing, harmonization and integration, under GDPR and ethics regulations. The roadmap implemented by Neutro-NARPS surpasses the obstacle of limited data due to small patient populations providing a long-term impact in the detection of novel biomarkers that may underlie disease progression/evolution and modify therapeutic interventions. The approach of centralized data integration/interpretation will result in the better evaluation of PROs related to QoL and development of novel tools for PROs that could be commercialized in the long-term. The integration of single-cell multi-omic technologies with bioinformatics pipelines will refine our understanding of drug- induced neutropenia by enabling precise modelling of neutrophil differentiation stages. This technological advancement is expected to uncover transcriptional and epigenetic aberrations, improving the design of safer, more effective and novel therapeutic interventions for CNP.

Societal impact: The Action’s short-term societal impact focuses on the raising of public awareness through the dissemination strategies for healthcare professionals, patients, decision makers and SMEs across Europe and beyond. A long-term impact of the Action is the application in the clinic of novel and potentially curative therapies that will increase the QoL and life expectancy of CNP patients. The clarification of the cause of CNP-related to novel therapies will give the chance for more patients with haematologic disease or AID to receive these highly effective therapies.

Economic impact: Although classified as a rare disease, severe CNP has a disproportionally high economic burden on health care systems due to the frequent hospitalization of patients and the cost of the  treatment  (life-long  G-CSF).  Neutro-NARPS  network  of  scientists,  stakeholders  and  patient advocates fosters collaborations that will accelerate research/innovation and application of novel treatments that will be curative for the patients and cost effective for the health care system.